General Information of Drug (ID: DM0CI4L)

Drug Name
N-[3H]methylhistamine Drug Info
Synonyms
1-Methylhistamine; Tele-methylhistamine; 501-75-7; N1-Methylhistamine; N-Telle-methylhistamine; 2-(1-methyl-1H-imidazol-4-yl)ethanamine; 2-(1-methyl-1H-imidazol-4-yl)ethan-1-amine; 1-Methyl-1H-imidazole-4-ethanamine; 1H-Imidazole-4-ethanamine, 1-methyl-; 1-Methyl-4-histamine; UNII-KCB81T4EOF; N(sup 1)-Methylhistamine; NSC 66736; N-tele-Methylhistamine; CHEBI:29009; 1-methyl-4-(b-aminoethyl)imidazole; 1-Methyl-4-(2-aminoethyl)imidazole; KCB81T4EOF; 1-Methyl-4-(beta-aminoethyl)imidazole; BRN 0110757
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3614
ChEBI ID
CHEBI:29009
CAS Number
CAS 501-75-7
TTD Drug ID
DM0CI4L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Patented Agent(s)
Drug(s) Targeting Histamine H4 receptor (H4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-3893787 DMC2FAL Atopic dermatitis EA80 Phase 2 [4]
JNJ-38518168 DM9UMIO Plaque psoriasis EA90.0 Phase 2 [5]
UR-63325 DME6X27 Allergic rhinitis CA08.0 Phase 2 [6]
Thioperamide DM8S593 Cognitive impairment 6D71 Terminated [7]
2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole DMZVBPG Discovery agent N.A. Investigative [8]
impromidine DMTDRPM Discovery agent N.A. Investigative [9]
burimamide DMZ2VYG Discovery agent N.A. Investigative [10]
Imetit DMMJ6NS Discovery agent N.A. Investigative [11]
[125I]iodophenpropit DMN4ABU Discovery agent N.A. Investigative [12]
(R)-alpha-methylhistamine DMKAW4P Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histamine H3 receptor (H3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pitolisant DM8RFNJ Excessive daytime sleepiness MG42 Approved [13]
SUVN-G3031 DM3BO8G Cognitive impairment 6D71 Phase 3 [14]
JNJ-17216498 DM1GRCU Narcolepsy 7A20 Phase 2 [15]
GSK239512 DMBJMZC Alzheimer disease 8A20 Phase 2 [16]
JNJ-39220675 DM0WY3H Alcohol dependence 6C40.2 Phase 2 [17]
AZD-5213 DMOZ04X Alzheimer disease 8A20 Phase 2 [18]
Bavisant DM6CVZ5 Attention deficit hyperactivity disorder 6A05.Z Phase 2 [19]
ABT-288 DM7X54F Alzheimer disease 8A20 Phase 2 [20]
SAR-110894 DMCLEXM Alzheimer disease 8A20 Phase 2 [18]
ABT-652 DMLEO2Z Diabetic neuropathy 8C0Z Phase 2 [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Diamine oxidase (AOC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [22]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [23]
Amiloride DMRTSGP Congestive heart failure BD10 Approved [24]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [25]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [26]
Methotrexate DM2TEOL Anterior urethra cancer Approved [27]
Aminoguanidine DMJQDUC Diabetic retinopathy 9B71.0 Phase 1 [24]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [28]
PMID28870136-Compound-48 DMPIM9L N. A. N. A. Patented [29]
Putrescine DMWE6V1 Burn and burn infection ND90-NE2Z Discontinued in Phase 2 [24]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H3 receptor (H3R) TT9JNIC HRH3_HUMAN Agonist [2]
Histamine H4 receptor (H4R) TTXJ178 HRH4_HUMAN Agonist [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Diamine oxidase (AOC1) OTRC220K AOC1_HUMAN Regulation of Drug Effects [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1241).
2 Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
3 Human kidney diamine oxidase: heterologous expression, purification, and characterization. J Biol Inorg Chem. 2002 Jun;7(6):565-79.
4 Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602.
5 The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015; 6: 65.
6 Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed). 2012 Jan 1;4:967-87.
7 Role of histamine in short- and long-term effects of methamphetamine on the developing mouse brain. J Neurochem. 2008 Nov;107(4):976-86.
8 Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor. Bioorg Med Chem. 2010 Jul 15;18(14):5441-8.
9 Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first pote... J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21.
10 Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther. 2001 Oct;299(1):121-30.
11 Histamine excites neonatal rat sympathetic preganglionic neurons in vitro via activation of H1 receptors. J Neurophysiol. 2006 Apr;95(4):2492-500.
12 Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem. 2008 Jun 12;51(11):3145-53.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61.
16 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
17 JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41.
18 SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
19 Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.
20 A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71.
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225)
22 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
23 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
24 Diamine oxidase is the amiloride-binding protein and is inhibited by amiloride analogues. J Biol Chem. 1994 Apr 1;269(13):9921-5.
25 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
26 Comparative Analysis of Transcriptomic Changes including mRNA and microRNA Expression Induced by the Xenoestrogens Zearalenone and Bisphenol A in Human Ovarian Cells. Toxins (Basel). 2023 Feb 9;15(2):140. doi: 10.3390/toxins15020140.
27 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
28 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
29 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.